Stock Taper
SCREENER COMPARE ANY 2 STOCKS
LENZ
LENZ THERAPEUTICS, INC.
NASDAQ
$4.68
▲ UP 0.43% (0.02)

KEY STATISTICS

Market Cap$146.74 M
52w High$50.40
52w Low$4.54
Dividend Yield89.01%
FrequencyWeekly
P/E-1.14
Volume475.32K
Shares Out.31.35M

COMPANY

LEADERSHIP

Evert Schimmelpennink
CHIEF EXECUTIVE
Evert Schimmelpennink

COMPENSATION 2026

Salary$690,000
Stock Awards$0
Incentive Plan Pay$538,200
All Other Comp.$14,000
Total$7,036,009

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 25, 2021
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
152

PRICE TARGET

Target High$7.00
Target Low$7.00
Target Median$7.00
Target Consensus$7.00

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$4.49M
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2024-03-22Reverse1:7

PRICE

$4.68 ▲ UP 0.43% (+$0.02)
OVERLAYS
$4.68$4.72$4.76$4.809:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM4.68

About LENZ Therapeutics, Inc.

https://www.lenz-tx.com ↗

LENZ Therapeutics, Inc. is a California-based biopharmaceutical company developing therapies like LNZ100 and LNZ101 in Phase III trials to improve vision, including presbyopia, in the U.S.

INDUSTRY

Biotechnology

A PRODUCT LENZ THERAPEUTICS, INC. IS KNOWN FOR

VIZZ™ (aceclidine ophthalmic solution) 1.44%
VIZZ™ (aceclidine ophthalmic solution) 1.44%

VIZZ™ is a preservative-free, once-daily eye drop for presbyopia, the first aceclidine-based treatment submitted to the FDA, with potential to be a best-in-class therapy for 128 million Americans.

COMPETITORS

COMPETITOR
ABBV COMPARE
BLCO COMPARE
COO COMPARE
GKOS COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License$5M $12.5M ▲$250K ▼$3.75M ▲
Product— — $1.65M $1.74M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
60
LISTED HERE
12
RANKED BY POSITION SIZE
VTI
0.00% · 819.6K
XSU.TO
0.00% · 530.4K
FESM
0.02% · 233.3K
SCHA
0.00% · 103.1K
ZPRR.DE
0.00% · 31.3K
HAPS
0.05% · 18.7K
XRSU.L
0.00% · 15.2K
RSSL
0.00% · 9.7K
IBBQ
0.01% · 1.8K
BIB
0.00% · 1.1K
WSGE
0.01% · 941
AVSC
0.00% · 195

INSTITUTIONAL OWNERSHIP

SHARES OWNED
83.95%
HOLDERS
257
TOP 12 OF 257 · RANKED BY POSITION SIZE
Ra Capital Management, L.P.
4.2M sh · $23.74M
Fmr LLC
3.7M sh · $59.24M
Alpha Wave Global, LP
3.6M sh · $20.52M
Versant Venture Management, LLC
2.7M sh · $123.76M
Blackrock, Inc.
2.3M sh · $13.02M
Squarepoint Ops LLC
1.7M sh · $9.92M
Ubs Group AG
1.6M sh · $25.15M
Abrdn Plc
1.5M sh · $8.79M
Millennium Management LLC
1.5M sh · $8.57M
Vanguard Group Inc
1.3M sh · $61.96M
Franklin Resources Inc
1.1M sh · $10.07M
Paradigm Biocapital Advisors LP
1.1M sh · $50M

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2

INSIDER TRADES

★
DIRECTOR, 10 PERCENT OWNER:
RA CAPITAL MANAGEMENT, L.P.
Purchase · 22.1K shares
2026-06-15
★
DIRECTOR
MCCOLLUM JAMES W
Purchase · 22.1K shares
2026-06-15
★
DIRECTOR
George Jeffrey P.
Purchase · 22.1K shares
2026-06-15
★
DIRECTOR
Drapkin Kimberlee C
Purchase · 22.1K shares
2026-06-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
NEUTRAL 1
OUTPERFORM 1
5 GRADES IN THE LAST 12 MONTHS
Piper Sandler NEUTRAL HC Wainwright & Co. BUY Citigroup BUY B of A Securities BUY Raymond James OUTPERFORM

SECTORS PEERS

PEERPRICE
NBTX$43.55COMPARE
GHRS$28.33COMPARE
TYRA$26.05COMPARE
MRVI$8.64COMPARE
SVRA$5.59COMPARE
ABUS$5.21COMPARE
GERN$1.52COMPARE
PRME$3.39COMPARE